Results 331 to 340 of about 164,355 (372)

Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.

New England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
E. Walsh, Gonzalo Pérez Marc, A. Zareba, A. Falsey, Q. Jiang, Michael Patton, F. Polack, C. Llapur, P. A. Doreski, Kumar Ilangovan, M. Rämet, Yasushi Fukushima, Nazreen Hussen, Louis J. Bont, Jose Cardona, E. Dehaan, Giselle Castillo Villa, M. Ingilizova, D. Eiras, T. Mikati, Rupal N Shah, Kathy Schneider, David Cooper, K. Koury, M. Lino, A. Anderson, K. Jansen, K. Swanson, A. Gurtman, W. Gruber, B. Schmoele-Thoma   +30 more
semanticscholar   +1 more source

Delayed Seasonal RSV Surge Observed During the COVID-19 Pandemic

Pediatrics, 2021
An unexpected positive outcome of the coronavirus disease 2019 pandemic has been the marked decline in illness associated with other respiratory viruses, likely due to the widespread use of masks and social distancing.
R. Agha, J. Avner
semanticscholar   +1 more source

RSV through the COVID‐19 pandemic: Burden, shifting epidemiology, and implications for the future

Pediatric Pulmonology, 2023
Respiratory syncytial virus (RSV) represents a major global healthcare burden, particularly in those under 5 years of age. There is no available vaccine, with treatment limited to supportive care or palivizumab for high‐risk children.
R. Stein, H. Zar
semanticscholar   +1 more source

RSV Epidemiology in Australia Before and During COVID-19.

Pediatrics, 2022
BACKGROUND AND OBJECTIVES COVID-19 public health measures have altered respiratory syncytial virus (RSV) epidemiology, resulting in an unseasonal summer epidemic in Australia in 2020.
G. Saravanos, Nan Hu, N. Homaira, D. Muscatello, A. Jaffe, A. Bartlett, N. Wood, W. Rawlinson, A. Kesson, R. Lingam, P. Britton   +10 more
semanticscholar   +1 more source

Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/ΔNS2/1030s in RSV-seronegative young children.

Journal of Infectious Diseases, 2023
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of pediatric lower respiratory illness (LRI) and a vaccine for immunization of children is needed.
R. Karron, C. Luongo, S. Woods, Jennifer Oliva, P. Collins, U. Buchholz   +5 more
semanticscholar   +1 more source

DSCG Reduces RSV‐induced illness in RSV‐infected mice

Journal of Medical Virology, 2008
AbstractRespiratory syncytial virus (RSV) is one of the pathogens generally associated with the common cold, lower respiratory infection, and exacerbation of asthma. Disodium cromoglycate (DSCG) is a safe and widely used drug for the prevention of bronchial asthma and allergic rhinitis attacks.
Koichi, Hashimoto, Syuichi, Mori, Yuko, Hashimoto, Hisatoshi, Kaneko, Kei, Ishibashi, Ken, Ishioka, Yukihiko, Kawasaki, Ray Stokes, Peebles, Mitsuru, Munakata, Mitsuaki, Hosoya, Tatsuo, Suzutani   +10 more
openaire   +2 more sources

Nirsevimab and Hospitalization for RSV Bronchiolitis.

New England Journal of Medicine
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life.
Zein Assad, A. Romain, Camille Aupiais, M. Shum, Cécile Schrimpf, Mathie Lorrot, H. Corvol, Blandine Prévost, Charlène Ferrandiz, Anna Giolito, Zaba Valtuille, Matthieu Bendavid, Jérémie F. Cohen, Julie Toubiana, Loic de Pontual, Camille F Delande, Michael Levy, Perrine Sée, Robert Cohen, Corinne Levy, François Angoulvant, Léa Lenglart, Maud Gits-Muselli, Valérie Biran, Kadiatou Diallo, Oluwafunmilola Alemede, Mohamed M. El Hebil, X. Durrmeyer, Géraldine Labouret, N. Casanovas, Benjamin Hallak, Olympe Maréchal, Camille Jung, Camille Bréhin, N. Ouldali   +34 more
semanticscholar   +1 more source